Werewolf Therapeutics Business Summary

Werewolf Therapeutics, Inc. (HOWL) is a clinical-stage biopharmaceutical company leveraging its proprietary PREDATOR® platform to engineer conditionally activated "INDUKINE" and "INDUCER" molecules designed to deliver potent immune-stimulatory cytokines directly to the tumor microenvironment while minimizing systemic toxicity. The company’s business model focuses on the clinical development of its internal pipeline—headlined by WTX-124 (IL-2) and WTX-330 (IL-12)—and the monetization of its platform through strategic licensing and collaboration agreements, such as its partnership with Jazz Pharmaceuticals. As of March 2026, Werewolf is operating under a streamlined structure following a 64% workforce reduction and is actively exploring strategic alternatives, including a potential sale or merger, to maximize the value of its clinical data. Within the competitive landscape of "masked" or "prodrug" immunotherapies, Werewolf competes directly with Xilio Therapeutics, CytomX Therapeutics, and Asher Bio, distinguishing itself through its specific protein engineering approach that utilizes non-cleavable linkers and steric blocking domains to optimize the therapeutic index of cytokines. The company was founded and is led by President and CEO Daniel J. Hicklin, Ph.D., a veteran drug developer who previously co-founded Potenza Therapeutics (acquired by Astellas) and held senior leadership roles at Merck and Schering-Plough. Following an executive restructuring in February 2026, the leadership team includes Michael Urban, who serves as the Principal Financial Officer and Corporate Controller, and Steven Bloom as Chief Business Officer. Werewolf’s strategic direction is supported by a high-pedigree board and investor base that includes RA Capital Management, Atlas Venture, and Bain Capital Life Sciences. This leadership team combines deep technical expertise in immuno-oncology with a proven track record of biotech exits, currently focused on navigating the company’s strategic review and advancing its lead INDUKINE programs through critical Phase 1/2 clinical readouts.